IMPORTANCE Small nodal tumor infiltrates (SNTI; isolated tumor cells and micrometastases) in sentinel lymph nodes and bone marrow micrometastases (BMM) were independently described as prognostic factors in patients with colon cancer.
S tandard treatment of colon cancer involves surgical resection according to oncological principles and adjuvant chemotherapy in stage III and high-risk stage I and II disease. The goal of adjuvant chemotherapy is to eradicate systemic micrometastatic disease not visible in the diagnostic workup procedures at the time of operation. This concept leads to a roughly 20% recurrence reduction in patients with node-positive (ie, stage III) colon cancer. 1, 2 For most patients with node-negative disease (ie, stage I and II), surgery is regarded to be the curative treatment. However, despite this curative attempt, up to 30% of patients with node-negative disease will develop disease recurrence, most likely owing to missed micrometastatic disease at initial tumor staging. 3, 4 Pathological standard processing with hematoxylin-eosin entails a considerable risk of missing micrometastases (ie, tumor deposits with a diameter of 0.2 mm to ≤2 mm, labeled as pN1 [mi] ) and isolated tumor cells (ITC; single tumor cells or clusters of tumor cells of 0.2 mm or less in diameter; pN0 [i+] ) in lymph nodes. [5] [6] [7] In previous reports, we have demonstrated that implementation of sentinel lymph node (SLN) mapping with intensive histopathological workup results in the detection of these small nodal tumor infiltrates (SNTI) in up to one-quarter of patients with node-negative colon cancer. 6, [8] [9] [10] Mounting evidence indicates that SNTI are associated with an increased risk of disease recurrence and death in so-called node-negative patients. 3, 9, 11 Similarly, small tumor infiltrates are found in the bone marrow of up to one-third of patients with stage I to III colon cancer and are also associated with decreased survival, as most recently demonstrated by our group. 12 However, to our knowledge, the association between disseminated tumor cells in lymph nodes and the bone marrow has not been investigated to date. The objective of the present study was 2-fold: first, to examine the association of SNTI in SLN with bone marrow micrometastases (BMM) in patients with stage I to III colon cancer; and second, to assess their prognostic effect on disease-free survival (DFS) and overall survival (OS).
Methods

Study Settings
This prospective study (clinicaltrials.gov identifier: NCT00826579) was performed at 3 university-affiliated hospitals in Switzerland (University Hospital Basel, Basel; Hospital Center Biel/Bienne, Biel/Bienne; and Cantonal Hospital Olten, Olten) from May 2000 until December 2006. The study protocol was approved by the ethical committees of all participating centers and was conducted in accordance with the Declaration of Helsinki. Inclusion and exclusion criteria of the study population have been reported previously. 12 In brief, patients with preoperatively verified stage I to III colon cancer met the inclusion criteria. Exclusion criteria for SLN mapping and bone marrow aspiration were stage IV disease, rectal cancer, history of other solid malignancies, prior abdominal cancer surgery, documented allergy to isosulfan blue, and current pregnancy or breast feeding. Written informed consent was obtained from all patients prior to surgery.
In all patients, open colon cancer resection according to oncological principles was performed. Tumors were staged according to the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumors, 6th edition. 13 The SLN mapping and bone marrow aspiration have been described in detail elsewhere. 14, 15 Briefly, bone marrow was aspirated from both iliac crests after induction of general anesthesia and before the start of the operation. Bone marrow aspirates were processed as described by our group previously. 15 Detection of 1 or more tumor cells was considered as bone marrow-positive. For the SLN mapping, isosulfan blue was injected in vivo into the subseroa around the tumor. Lymph nodes staining blue within 10 minutes after dye application were marked with a suture and collected as SLN and then processed according to our previously reported protocol. 6, 14 The protocol consists of 5 serial sections of each SLN that were obtained at 3 different representative levels. The first section of each level was stained with hematoxylin-eosin. If no metastatic deposits were detectable by hematoxylin-eosin, the fourth section of each level was immunostained with the pancytokeratin marker AE1/AE3 (DakoCytomation). If micrometastases were detected by hematoxylin-eosin or immunohistochemistry, node-negative patients were upstaged to stage III (pN1[mi]). If ITC were detected in the SLN, patients were not upstaged according to the TNM Classification of Malignant Tumors, 6th edition (pN0[i+]). 13 All pathologists were blinded regarding the tumor histology. Adjuvant chemotherapy was recommended for patients with stage III cancer and to patients with stage II cancer featuring high-risk factors (ie, less than 12 lymph nodes analyzed, T4 tumor, lymphovascular or perineural invasion, poorly differentiated histology, or tumor perforation). Bone marrow positivity was not considered an indication for adjuvant chemotherapy. Follow-up was performed according to the national surveillance guidelines for patients after curative colon cancer resection. 16 
Statistical Analyses
Statistical analyses were performed in October 2016 with the R statistical software version 3.2.5 (The R Foundation). A 2-sided P value < .05 was considered statistically significant. 
Key Points
Association of SNTI and BMM
An association between the presence of SNTI and BMM was not observed in either the entire cohort (κ, −0.07; 95% CI, −0.29 to 0.14; P = .49) or the subset of patients with stage I and II cancer (κ, −0.13; 95% CI, −0.4 to 0.14; P = .34). The occurrence of SNTI did not predict the occurrence of BMM in univariable logistic regression (odds ratio [OR], 0.64; 95% CI, 0.22-1.67; P = .37) or in multivariable logistic regression (OR, 1.09; 95% CI, 0.34-3.28; P = .88) ( Table 2) . Similarly, the occurrence of BMM did not predict the occurrence of SNTI in univariable logistic regression (OR, 0.64; 95% CI, 0.22-1.67; P = .37) or multivariable logistic regression (OR, 1.19; 95% CI, 0.38-3.64; P = .77) ( Table 3) . In multivariate analysis, BMM were identified as a negative prognostic factor for DFS (HR, 2.07; 95% CI, 1.06-4.06; P = .04) and OS (HR, 2.68; 95% CI, 1.26-5.70; P = .01) ( Table 3) . When considering the subgroup of stage I and II patients, SNTI and BMM were no longer independent prognostic factors (data not shown). 
Discussion
The present investigation provides compelling evidence that tumor cell dissemination to the SLN and to the bone marrow are independent events in patients with colon cancer. Moreover, while both SNTI and BMM are independent negative prognostic factors regarding DFS and OS, the combined occurrence is associated with significantly worse prognosis compared with either one of them. In our cohort, SNTI were detected in almost one-fifth of patients considered to be lymph node-negative with conventional histopathological examination. Bone marrow micrometastases were detected in more than one-third of patients. These detection rates compare favorably with previously published results by our and other groups. 6, 12, 14, 20, 21 Interestingly, only a very small subgroup of patients showed simultaneous occurrence of SNTI and BMM. Similar observations were made in patients with early breast cancer and melanoma, reporting simultaneous lymphatic and hematogenic dissemination in one-fifth of patients. 15, [22] [23] [24] Two of these studies assessed the correlation of micrometastases in the SLN and the bone marrow in patients with early breast cancer and could not detect any association. 23, 24 According to the common concepts of cancer growth and progression, earliest tumor cell dissemination is thought to initially follow the lymphatic vessels toward the first draining lymph nodes prior to systemic (ie, hematogenic) spread. 25 The observations made in the present study directly challenge this concept in colon cancer. Although hematogenic tumor cell spread has been reported in early stages of colon cancer, its connection with lymphatic dissemination and the chronology of these events have never been fully understood. 4, 22, 26, 27 The presented results demonstrate that tumor cell dissemination is not restricted to one typical sequence and therefore call into question the very concept of sequential tumor cell spread. In the present cohort, patients with SNTI or BMM had a significantly decreased DFS and OS that was even worse when SNTI and BMM occurred simultaneously in the same patient ( Figure 1 and Figure 2 ). Both SNTI and BMM were identified as independent negative prognostic markers. However, as the detection of SNTI has no therapeutic consequence in patients with stage III colon cancer, we performed a separate analysis with node-negative patients (ie, with stage I and II cancer) only. It revealed that SNTI and/or BMM were still associated with decreased survival but were no longer independent prognostic markers below the level of statistical significance, most likely owing to the smaller sample size. Mounting evidence suggests that SNTI are indeed a negative prognostic marker in stage I and II colon cancer. 3, 9, 11, 28 By contrast, the literature regarding the prognostic significance of BMM is very scarce but suggests an association with negative survival. 12, 29 In addition, a 2015 study 27 detected a negative prognostic effect of circulating tumor cells obtained from (100) 61 (100) 15 (100) 40 (100) 
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Tumor Cell Dissemination to Lymph Nodes and Bone Marrow in Nonmetastasized Colon Cancer peripheral blood samples in patients with stage I to III colorectal cancer. This study compares favorably with the present results, as tumor cell dissemination to the peripheral blood and the bone marrow both represent hematogenous spread. The growing evidence raises the question whether patients with disseminated tumor cells might benefit from adjuvant chemotherapy. The current TNM Classification of Malignant Tumors, 7th edition, 30 recommends adjuvant chemotherapy for patients with lymph node micrometastases but not for patients with ITC or BMM. With the change from the 5th to the 6th edition of the TNM Classification of Malignant Tumors in 2002, ITC were newly allocated as pN0 and micrometastases as pN1. 13, [31] [32] [33] Remarkably, the discrimination between micrometastases and ITC is chosen randomly at 0.2 mm and not made on the basis of measured survival differences. 5, 34, 35 Because of such ambiguities, pathological and oncological practice differs significantly even between countries in Western Europe. Germany and Switzerland have adopted the TNM Classification of Malignant Tumors, 7th edition, 30 classifying ITC as pN0 and offering adjuvant chemotherapy to patients with micrometastases staged as pN1. Conversely, in the United Kingdom, colon cancer is staged according to the TNM Classification of Malignant Tumors, 5th edition. 36 Any metastatic deposit in the lymph node is staged as pN1, suggesting adjuvant chemotherapy for patients with ITC and micrometastases. 33 In the Netherlands, colon cancer is staged according to the TNM Classification of Malignant Tumors, 5th edition, 36 but ITC and micrometastases are staged as pN0, not suggesting adjuvant chemotherapy for these patients. 37 These essential differences in colon cancer treatment are highly unsatisfactory and emerged mainly because of an inconclusively held debate. It is therefore of utmost importance to keep this debate going and to further seek clarification.
Limitations
Our study had limitations. First, this is a cohort study and not a randomized clinical trial, and some confounders may therefore be present. However, baseline characteristics between the patient groups are comparable, and the presence of a relevant selection bias is unlikely. Second, the lower patient number for the stage I and II subset analysis was most probably responsible for the lack of significant results for the association of SNTI as well as BMM with survival in this subgroup. However, the negative prognostic effect of SNTI and BMM was highly significant for stage I to III cancer. Finally, the determination of mismatch repair protein expression and microsatellite instability were not standard procedures at the time 
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Tumor Cell Dissemination to Lymph Nodes and Bone Marrow in Nonmetastasized Colon Cancer of patient inclusion, and we therefore cannot report these data. Regardless, to our knowledge, this study is the first in the literature to investigate the association between SNTI and BMM in patients with colon cancer.
Conclusions
Our results clearly demonstrate that hematogenic and lymphogenic tumor cell dissemination are already of equal importance at early disease stages. Therefore, the traditional idea of sequential metastatic spread must be seriously doubted. These findings also raise the question if standard lymph node dissection and evaluation are sufficiently accurate to identify patients at risk of disease recurrence. Our results suggest that lymph node dissection may only play a subordinate role and that more meticulous techniques, like SLN mapping, bone marrow aspiration and/or semiautomatic messenger RNA amplification, 38 will be of higher importance for the detection of tumors' real metastatic potential and for individual patient treatment. 
